-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Jazz Pharmaceuticals plc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2012 to Q1 2024.
- Jazz Pharmaceuticals plc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$66.4M, a 0.49% decline year-over-year.
- Jazz Pharmaceuticals plc annual Deferred Income Tax Expense (Benefit) for 2023 was -$260M, a 11% increase from 2022.
- Jazz Pharmaceuticals plc annual Deferred Income Tax Expense (Benefit) for 2022 was -$292M, a 522% decline from 2021.
- Jazz Pharmaceuticals plc annual Deferred Income Tax Expense (Benefit) for 2021 was $69.2M.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)